Prognostic Contribution of the New Immunoglobulin (Ig) Biomarkers (Freelite™ and Hevylite™) in Waldenstrom’s Macroglobulinemia (WM)

MC Kyrtsonis; Efstathios Koulieris; Dimitrios Maltezas; Τατιάνα Τζένου; Stephen Harding; Efstathios Kastritis; Nikolitsa Kafassi; Vassiliki Bartzis; Anna Efthymiou; K. Bitsanis; Maria Gavriatopoulou; Evangelos Terpos; Christina Kalpadakis; M. Angelopoulou; T. P. Vassilakopoulos; A.R. Bradwell; P Beris; G. Pangalis; Panayiotis Panayiotidis; Meletios A Dimopoulos

doi:10.5923/j.ajmms.20120206.05

Abstract

1 min read

Clinical utility of serum free light chains (sFLC) and heavy chain (HLC) IgM were assessed, using Freelite and Hevylite assays in 70 WM patients. The result showed that median involved (i) sFLC -kappa and -lambda were 45.6 and 78.3mg/L respectively; median sFLC (kappa+lambda) was 67.4 mg/L. While, median FLCR (involved/uninvolved FLC ratios) were 2.7 and 6.9 in ikappa- and ilambda -restricted patients respectively. Moreover, increased isFLC, sFLC (kappa+lambda) and FLCR were correlated significantly with shorter time to first treatment (TFT) and adverse survival (OVS). Median iIgM-kappa and iIgM -lambda were 25.4 and 34.8g/L respectively; median HLCR (involved/uninvolved HLC ratios) were 185.5 and 101.9 in kappa- and lambda- restricted patients respectively. In addition, the increased iHLC and HLCR correlated significantly with shorter TFT. Hence, sFLC and HLC measurements appeared to be both prognostic in WM.

Related publications

Article2004

Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression

Meletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, Athanasios K. Anagnostopoulos, Constantinos Zervas, Athanassios Zomas, Marie Christine Kyrtsonis, Nicolaos Anagnostopoulos, Gerassimos A. Pangalis, Donna M. Weber

Article2006

International Prognostic Scoring System (IPSS) for Waldenstrom’s Macroglobulinemia (WM).

Pierre Morel, Alain Duhamel, Paolo G. Gobbi, Meletios A Dimopoulos, Madhav V. Dhodapkar, Jason McCoy, Enrique M. Ocio, Ramón García‐Sánz, Steven P. Treon, Véronique Leblond, Robert A. Kyle, Bart Barlogie, Giampaolo Merlini

Article2009

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).

Meletios A Dimopoulos, Marie‐Christine Kyrtsonis, Evdoxia Hadjiharissi, Argiris Symeonidis, Eurydiki Michalis, Panayiotis Repoussis, Costas Tsatalas, Michalis Michael, Anastasia Sioni, Ekaterini Stefanoudaki, Zafiris Kartasis, Michael Voulgarelis, Sosana Delimpasi, Efstathios Kastritis, Maria Gavriatopoulou, Efstathios Koulieris, Dimitra Gika, Paraskevi Roussou, Nikolaos Anagnostopoulos, Evangelos Terpos, Theofanis Economopoulos,

Article2005

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Athanasios K. Anagnostopoulos, Steven P. Treon, Konstantinos Zervas, Andrew R. Branagan, Dimitra Gika, Athanasios Zomas, Marie Christine Kyrtsonis, Amalia Vassou, Nikolaos Anagnostopoulos, Gerasimos Pangalis, Meletios A Dimopoulos

Article2005

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Athanasios K. Anagnostopoulos, Konstantinos Zervas, Evangelos Terpos, Marie Christine Kyrtsonis, Argiris Symeonidis, Dimitra Gika, Konstantinos L. Bourantas, Athanasios Zomas, Nikolaos Angnostopoulos, Gerasimos Pangalis, Meletios A Dimopoulos